Pune-based Serum Institute of India (SII) joined hands with Gavi in a Vaccine Alliance with the Bill and Melinda Gates Foundation, to speed up the process of manufacture and delivery of up to 100 million doses of Covid-19 vaccines for India and other third world countries.
Adar Poonawalla, CEO and Owner of Serum Institute of India informed on Friday, “I would like to thank @BillGates, @gatesfoundation, and @GaviSeth for this key partnership of risk-sharing and manufacturing of 100 million doses, which will also ensure equitable access at an affordable price to many countries around the world,”
The Bill and Melinda Gates Foundation will lead the onus of at-risk funding of USD 150 million to Gavi, which will then be utilized to support the Serum Institute to manufacture the potential vaccine candidate.
“The funding will support at-risk manufacturing by SII for candidate vaccines from AstraZeneca and Novavax, which will be available for procurement if they are successful in attaining full licensure and WHO prequalification,” SII added.
The Drugs Controller General of India (DCGI) had earlier granted permission to the Serum Institute to conduct phase 2 and 3 of human clinical trials in India. The virus has so far claimed the lives of about 40,000 people and infected 2 million people across the nation with an uncompromising growth in the daily number of cases globally.
The potential Covid-19 vaccine manufactured by SII under the partnership is likely to be made available to at least 92 countries at a fairly affordable price.